Management of candidiasis in the intensive care unit

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue SUPPL. 1, 2008, Pages 31-34

  Schelenz, Silke ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

ICUs; Prophylaxis; Treatment

Indexed keywords

ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG EFFECT; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; REVIEW;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS;

EID: 41949123373     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm430     Document Type: Article

References (43)

1. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24
2. Diekema DJ, Messer SA, Brueggemann AB et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organism study. J Clin Microbiol 2002; 40: 1298-302.
3. Schelenz S, Gransden WR. Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period. Mycoses 2003; 46: 390-6.
4. Trick WE, Fridkin SK, Edwards JR et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30.
5. Rangel-Frausto MS, Wiblin T, Blumberg HM et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of blood-stream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253-8.
6. Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
7. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33: 177-86.
8. Wey SB, Mori M, Pfaller MA et al. Risk factors for hospital-acquired candidaemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-53.
9. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G et al. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004; 10: 550-5.
10. Blot SI, Vandewoude KH, Hoste EA et al. Effects of nosocomial candidemia on outcome of critically ill patients. Am J Med 2002; 113: 480-5.
11. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
12. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidaemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
13. Nolla-Salas J, Sitges-Serra A, Leon-Gil C et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
14. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
15. Olaechea PM, Palomar M, Leon-Gil C et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Dis 2004; 23: 323-30.
16. Petri MG, König J, Moecke HP et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Intensive Care Med 1997; 23: 317-25.
17. Charles PE, Dalle F, Aube H et al. Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005; 31: 393-400.
18. Richet HM, Andremont A, Tancrede C et al. Risk factors for candidaemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991; 13: 211-5.
19. Reagan DR, Pfaller MA, Hollis RJ et al. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990; 28: 2733-8.
20. Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
21. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
22. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
23. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchanges and the duration of candidaemia. Clin Infect Dis 1995; 21: 994-6.
24. Donahue SP, Greven CM, Zuravleff JJ et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101: 1302-9.
25. Pfaller MA, Diekema DJ, Jones RN et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-9.
26. Marchetti O, Bille J, Fluckiger et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
27. Poikonen E, Lyytikäinen O, Anttila V-J et al. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-90.
28. Slavin MA, Szer J, Grigg AP et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004; 34: 192-200.
29. Flückiger U, Marchetti O, Bille J et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006; 136: 447-63.
30. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
31. Ruhnke M, Kuse E, Chetchotisakd P et al. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-722. American Society for Microbiology, Washington, DC, USA.
32. Reboli A, Rotstein C, Pappas P et al. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract M-718. American Society for Microbiology, Washington, DC, USA.
33. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42
34. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
35. Park S, Kelly R, Nielsen Kahn J et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
36. Gauthier GM, Nork TM, Prince R et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: e27-8.
37. Stratov I, Gottlieb T, Bradbury R et al. Candidaemia in an Australian teaching hospital: relationship to central line and TPN use. J Infect 1998; 36: 203-7.
38. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
39. Ables ZA, Blummer NA, Valainis GT et al. Fluconazole prophylaxis of severe Candida infection in trauma and post surgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000; 9: 169-75.
40. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
41. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.
42. Garbino J, Lew DP, Romand JA et al. Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17.
43. Shorr AF, Chung K, Jackson WL et al. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005; 33: 1928-35.